|
Home : Unsafe Drugs : Avandia : Newsfeeds : Glaxo Faces ‘War for Talent’ Against Pfizer, Sanofi in Emerging Markets Glaxo Faces ‘War for Talent’ Against Pfizer, Sanofi in Emerging Markets
Glaxo’s revenue in the U.S. declined 11 percent last year and in Europe it fell 6 percent, after the company stopped promoting its Avandia drug worldwide because of studies linking it to increased risk of heart attacks, and generic competition eroded ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




